OraSure Technologies (NASDAQ:OSUR) Downgraded by StockNews.com to Hold

StockNews.com downgraded shares of OraSure Technologies (NASDAQ:OSUR) from a buy rating to a hold rating in a research report report published on Saturday.

Several other equities analysts also recently weighed in on the company. Evercore ISI lifted their target price on OraSure Technologies from $4.50 to $5.00 and gave the company an in-line rating in a research report on Wednesday, August 7th. JPMorgan Chase & Co. lowered their price objective on OraSure Technologies from $7.00 to $6.00 and set a neutral rating on the stock in a research report on Monday, May 13th. Three analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. According to data from MarketBeat, OraSure Technologies currently has an average rating of Hold and an average price target of $6.67.

OraSure Technologies Price Performance

Shares of OraSure Technologies stock opened at $4.24 on Friday. OraSure Technologies has a 1-year low of $3.91 and a 1-year high of $8.45. The company’s fifty day simple moving average is $4.28 and its 200-day simple moving average is $5.37. The stock has a market capitalization of $313.59 million, a PE ratio of 14.13 and a beta of 0.09.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Tocqueville Asset Management L.P. lifted its position in shares of OraSure Technologies by 20.0% in the first quarter. Tocqueville Asset Management L.P. now owns 15,089 shares of the medical instruments supplier’s stock valued at $93,000 after acquiring an additional 2,512 shares in the last quarter. AXA S.A. raised its stake in OraSure Technologies by 2.5% during the 2nd quarter. AXA S.A. now owns 161,614 shares of the medical instruments supplier’s stock valued at $688,000 after purchasing an additional 3,997 shares during the period. AJOVista LLC purchased a new position in OraSure Technologies in the 4th quarter worth approximately $39,000. SG Americas Securities LLC boosted its stake in OraSure Technologies by 46.4% in the 2nd quarter. SG Americas Securities LLC now owns 17,125 shares of the medical instruments supplier’s stock worth $73,000 after purchasing an additional 5,431 shares during the period. Finally, Lazard Asset Management LLC grew its holdings in OraSure Technologies by 12.9% during the 1st quarter. Lazard Asset Management LLC now owns 56,908 shares of the medical instruments supplier’s stock valued at $349,000 after buying an additional 6,500 shares in the last quarter. Institutional investors own 93.50% of the company’s stock.

OraSure Technologies Company Profile

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company's products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.